Glioblastoma adaptive global innovative learning environment

Recruiting

18 years - 99 years

All

Phase 2

10 participants needed

1 Location

Brief description of study

This research study aims to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. The investigational drugs that will be used in this research study are temozolomide for newly diagnosed glioblastoma and Lomustine for recurrent glioblastomas.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Glioblastoma
Age: 18 years - 99 years
Gender: All

Updated on 04 Aug 2024. Study ID: 834751

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Glioblastoma adaptive global innovative learning environment

Brief description of study

Eligibility of study

Find a site

Interested in the study